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ABSTRACT
Pathologically, Alzheimer’s disease is a result of aggregation of amyloid peptides and protein tau in the brain forming
neurofibrillary tangles which are highly toxic to neuronal circuits in the brain. Recent evidences report that apart from
aging, estrogen deficiency is one of the risk factors predisposing to the development of Alzheimer’s disease. Isoflavones, also known as phytoestrogens, are metabolized by the body forming compounds that are known to interfere with
neurotoxic pathways and through their anti-fibrillization effects they play a role in reducing apoptosis of neurons and
glial cells and promote axonal regeneration. Experimental studies on transgenic models with Alzheimer’s disease as
well as various observational and clinical trials suggest that dietary interventions with Isoflavones may have a significant
role in improving portions of memory, cognition and decreasing the risk of Alzheimer’s disease.
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INTRODUCTION

main dietary groups of flavonoid include [1] flavonols [2]
flavones [3]anthocyanidins, [4]flavanones, [5]flavanols, [6]
Isoflavones (12). Upon ingestion, these compounds are
metabolized to take different forms in the body (13, 14)
indirectly protecting the neuronal population from degradation, stimulating neurogenesis and augmenting
neuronal functions (15-18). Isoflavones, one of the aforementioned subtypes of flavonoids, has recently gained
significant attention and is being studied extensively.
Ranging from experimental studies on transgenic
models (19, 20) to interventional trials using dietary supplements rich in isoflavones, it has shown to improve cognition and memory (21-23).Isoflavones are derived from
plants. So far soy-beans are the most abundant source
of isoflavones whilelegumes, grains and vegetables are
other good sources containing small amount of isoflavones (24, 25). Chemically, isoflavones have a non-steroidal
structure similar to estrogens in humans and animals,
hence they are also known as phytoestrogens. In the
digestive tract, the primary isoflavones (genistin, daidzin,
and glycitin) are hydrolyzed into their respective
aglycones (genistein, daidzein, and glycitein) which are
metabolically active, before being absorbed into the
system (26, 27). There has been scanty literature about
effects of Flavonoids and its subtype Isoflavones on
cognitive improvement and neurodegenerative diseases.
The purpose of this article is to bring together the
evidence regarding positive effects of flavonoids, on
cognition, and memory, particularly focusing on Isoflavones.

Ageing, along with dietary habits are the major risk
factors that contribute to the development of neurodegenerative diseases. Dementia is one of the types of
neurodegenerative diseases. As age progresses, it leads
to the loss of brain function affecting cognitive thinking,
memory and behavior. Prevalence of dementia is
predicted to double every 20 years worldwide and
estimated to reach 115.4 million by 2050 (1).
Alzheimer’s disease (AD) is a form of Dementia. Pathologically, it is the aggregation of amyloid peptides and
protein tau in the brain. These proteinstake a form of
neurofibrillary tangles which are highly toxic to neuronal
pathways in the brain (2). Evidences suggest that, apart
from aging, deficiency of estrogen is also one of the
factors involved in causing AD, by exposing neurons to
toxic insults, including A-beta, as a result of which postmenopausal women are at a significant risk of developing AD (3,4). Unfortunately, current drug treatments have
failed to show positive results in the prevention of neurodegenerative diseases (5, 6). Consequently, there is an
increasing interest in dietary interventions. Various interventional studies have been conducted globally demonstrating the protective role of antioxidants against AD.
These antioxidants include Vitamins C, E, Beta Carotene
and Flavonoids (7-10). Flavonoids belong to a group of
polyphenolic compounds. These components are found
in plants, and are included in human diets in the form of
vegetables, cereals, tea, wine, and fruit juices (11). The
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activation and their anti-oxidant properties which shield
against the oxidative stress on the neurons (38). Interferences in these pathways in turn reduce apoptosis of
neurons and glial cells and promote axonal regeneration.
Experimental studies conducted in-vitro, demonstrated
the direct influence of isoflavonoids on proteins involved
in the pathology of Alzheimer’s disease. Amyloid beta
solutions were prepared, which were then fibrillized.
When incubated with Gly and Gen, the experiment
successfully demonstrated their anti-fibrillization effects.
Gly and Gen were shown to directly interact with the
fibrils and inhibited the fibrillization in a dose-dependent
manner (40). Prior works on isoflavones have also shown
that Gly, Gen and Daidzein (Dai), another form of hydrolyzed isoflavone to bind the monomeric form of
transthyretin protein (TTR) (41) which is a protein that
binds to the amyloid-beta preventing them to accumulate into plaques (42). However the mechanisms through
which isoflavones inhibit protein fibrillation are yet to be
analyzed. Apart from anti-fibrillization effects, Isoflavones were reported to play a role against cell injuries
caused by amyloid beta. In recent studies conducted on
transgenic models, isoflavones were indicated to reduce
the oxidative injury induced by amyloid beta (43). It was
also reported that Isoflavones can rescue neurons from
amyloid beta induced cell death by interfering with the
p38 MAP kinase pathway (44). Mixed soy isoflavones
were shown toimprove parameters related to aging and
Alzheimer's disease in C57BL/6J mice treated with
d-galactose (19). In another study, it was demonstrated
that due to isoflavone’s ability to generate PPAR-γ
expression, it can have inhibitory effects against the
inflammation associated with amyloid beta in cultured
neuronal cells (45). Hence, the anti-amyloidogenic effects
of soy isoflavones may be beneficial in dementia and AD
and if supplemented at an earlier age, may be helpful in
inhibiting or limiting the disease process. Isoflavones
also possess the ability to bind to estrogen receptors.
Gen and Dai bind with a greater affinity to the estrogen
receptor-beta (46). This can be linked to the fact that in
the brain, there is a high concentration of estrogen
receptor-beta in the hippocampus (47,48), which might
explain one of the mechanisms through which soy isoflavones benefit episodic memory.

There are several in vitro studies showing that green tea
extract, a source of flavonoids, could protect neurons
from the amyloid beta-induced damages in Alzheimer’s
disease (28, 29). Researches conducted on transgenic
models, focused on the processes of the amyloid
precursor protein (APP) proteolysis and amyloid beta
metabolism in the degenerating neurons of the brain,
which is the primary pathology in Alzheimer’s disease
and can be possible targets in its therapy. APP can be
processed by two pathways: 1) a nonamyloidogenic
pathways which involve cleavage of APP to soluble APP
by the alpha-secretase activity and 2) a formation of the
amyloidogenic beta peptides by the beta- and gamasecretases. Various synthetic and naturally occurring
compounds have been analyzed for their efficacy in the
modulation of these pathological events. Among them,
epigallocatechingallate (EGCG) is able to regulate the
proteolytic processing of APP both in vitro and in vivo
(30)
.It has been demonstrated that flavonoids could
promote the nonamyloidogenic alpha-secretase pathway and reduce the formation of amyloid beta-fibrils (30)
Flavonoids also seem to have an effect on a number of
intracellular signaling pathways such as mitogenactivated protein kinases (MAPKs) (31), protein kinase C
(30)
, and phosphatidylinositol-3-kinase (PI-3 kinase)-Akt
pathways (32). Oxidative stress seems to be one of the
major stimuli for the MAPKs cascade, which might
ultimately lead to cell survival/death. MAPKs pathways
play a crucial role as transducers of extracellular stimuli
into a series of intracellular phosphorylation cascades.
These pathways exert important role in neuronal protection against a variety of insults and are essential to cell
survival (33). In vitro studies demonstrate that EGCG could
induce MAPKs pathways including extracellular signalregulated kinase (ERK), c-Jun N-terminal kinase (JNK),
and p38 MAPK, which protect cells (34). For instance, in
neuronal cell line and primary neuronal cultures, EGCG
could prevent the decline in ERK1/2 induced by
6-hydroxydopamine or oxidized low-density-lipoproteins
(35,36)
, which are associated to attenuation of neuronal
death and cellular injury by oxidative stress (37).

OBSERVATIONAL AND CLINICAL TRIALS

Effects of Soy Isoflavones on transgenic models
with Alzheimer’s Disease

Humans are predisposed to neurodegenerative diseases
as they age beyond 70 years(49). Recent nutritional
studies conducted on populations indicate that
increased intake of fruits and vegetables are associated
with improved cognition and reduced risk of senile debilitating brain diseases(50, 51, 52). Blue-berry derived flavonoids were shown to indirectly interact with certain brain
areas such as the hippocampus and dentate gyrus and

Focusing specifically on Soy Isoflavonoids, It has been
reported that the hydrolyzed forms of soybeans and
isoflavones, including glycitein (Gly) and genistein (Gen),
have a role in inhibiting Amyloid beta-induced apoptosis
in cultured cell (38). Mechanisms outlined by various
studies include the protective effects of isoflavoneinduced arginase1 activity (39), inhibition of caspase
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hence were associated with improvement in spatial
memory (53, 54). In a cross-sectional study conducted over
8335 subjects concluded that intake of isoflavones were
inversely associated with plasma levels of C-reactive
protein as well as other inflammatory markers in the
blood, suggesting the anti-inflammatory role of isoflavones (55). An observational study in a general Japanese
population, investigated seven different dietary patterns
and their potential association with the risk of dementia.
Soybean and soybean-based products were one of the
dietary patterns observed. The results revealed that a
higher adherence to a diet containing high proportions of
soybean and soybean products were associated with
reduced risk of dementia in the studied population (56).
Most interventional clinical trials including Isoflavones
were conducted on post-menopausal women.In a study,
176 post-menopausal women were supplemented with
80 mg of Isoflavones per day, followed for 6 months,
revealed no significant association with better performance on neuropsychological tests (57). Anotherstudy
involved 36 post-menopausal females, were given 60mg
of Isoflavones regularly in a span of 12 weeks, showed
significant improvement in memory and sustained attention tasks (58), similarly in a clinical trial, 25g of soy
protein in powder or bar form containing 154 mg of total
Isoflavones were administered in a population of 313
healthy post-menopausal women, for a period of 2.5
years, the results deduced that there was a significant
improvement in visual episodic memory after the intervention (59). Better mood was also observed in 78
healthy post-menopausal females after they received
treatment with 60mg Isoflavones for 6 months(60). In
another study 78 elderly individuals with mild cognitive
deficits were given 300mg per day of soy for 6 months,
and the results concluded that treatment with soy
supplementation caused an significant improvement in
memory function of the elderly as compared to the
placebo group(61). Short-term studies conducted over
young healthy volunteers also presented positive results.
In a study, 16 young healthy females and 7 young
healthy males were asked to consume 900g of
soybeans for a period of 1 week. Mental Rotation and
Spatial Visualization psychological tests were conducted
over the volunteers during the days of the sampling. The
results reported that there was a significant improvement in the Mental Rotation and Spatial Visualization
psychological tests post-treatment(21,22). Overall, clinical
trials suggest that soy Isoflavones supplementation may
benefit portions of memory and cognition, but less
effects on global cognition. It may also prevent the
decline in verbal memory observed with aging. More
long-term clinical trials are needed on larger populations
to detect the role of soy Isoflavones on patients
diagnosed with Alzheimer’s disease. Skewing the dietary

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

patterns towards higher proportions of soy Isoflavones
may be beneficial for the population at high risk for
developing Alzheimer’s disease.
CONCLUSION
In conclusion, soy Isoflavones may have a protective role
against Alzheimer’s disease. Experimental studies on
transgenic models have shown positive effects of soy
Isoflavones on the biological mechanisms involved in the
pathology of Alzheimer’s disease. Since most of the
studies are conducted on transgenic models with scanty
observational and clinical trials conducted over small
sample sizes, it cannot be concluded that Isoflavones
may prevent AD in high risk population. More research is
needed in this area for a clinical census on the benefits
of soy-derived Isoflavones.
REFERENCES
1.

2.

3.

4.

5.
6.
7.

8.

9.

42

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W,
Ferri CP. The global prevalence of dementia: a
systematic review and metaanalysis. Alzheimers
Dement. 2013 Jan;9(1):63-75 e2.
Baptista FI, Henriques AG, Silva AM, Wiltfang J, da
Cruz ESOA. Flavonoids as therapeutic compounds
targeting key proteins involved in Alzheimer's
disease. ACS ChemNeurosci. 2014 Feb 19;
5(2):83-92
Simpkins JW, Green PS, Gridley KE et al. Role of
estrogen replacement therapy in memory enhance
ment and prevention of neuronal loss associated
with Alzheimer’s Disease. Brain res. 1997 Sep;
103(3A): 195-253
Green PS, Simpkins JW. Estrogen and estrogen-like
non-feminizing compounds. Their role, the preven
tion and treatment of Alzheimer’s disease. Ann NY
acad sci. 2000;924:93-8
Legos JJ, Tuma RF, Barone FC. Pharmacological
interventions for stroke: failures and future. Expert
OpinInvestig Drugs. 2002 May;11(5):603-14.
Narayan RK, Michel ME, Ansell B, Baethmann A,
Biegon A, Bracken MB, et al. Clinical trials in head
injury. J Neurotrauma. 2002 May;19(5):503-57.
Kalmijn S, Feskens EJ, Launer LJ, Kromhout D.
Polyunsaturated fatty acids, antioxidants, and
cognitive function in very old men. Am J Epidemiol.
1997 Jan 1;145(1):33-41.
Engelhart MJ, Ruitenberg A, Meijer J, Kiliaan A, van
Swieten JC, Hofman A, et al. Plasma levels of
antioxidants are not associated with Alzheimer's
disease or cognitive decline. Dement Geriatr
CognDisord. 2005;19(2-3):134-9.
Letenneur L, Proust-Lima C, Le Gouge A, Dartigues
JF, Barberger-Gateau P. Flavonoid intake and cogni
tive decline over a 10-year period. Am J Epidemiol.

VOL. 9 (2) APR - JUN 2014

10.

11.
12.

13.

14.

15.

16.
17.
18.

19.

20.

21.

22.

23.

2007 Jun 15;165(12):1364-71.
Velho S, Marques-Vidal P, Baptista F, Camilo ME.
Dietary intake adequacy and cognitive function in
free-living active elderly: a cross-sectional and
short-term prospective study. ClinNutr. 2008 Feb;
27(1):77-86.
Manach C, Scalbert A, Morand C, Remesy C, Jime
nez L. Polyphenols: food sources and bioavailability.
Am J ClinNutr. 2004 May;79(5):727-47.
Williams RJ, Spencer JP. Flavonoids, cognition, and
dementia: actions, mechanisms, and potential
therapeutic utility for Alzheimer disease. Free
RadicBiol Med. 2012 Jan 1;52(1):35-45.
Manach C, Williamson G, Morand C, Scalbert A,
Remesy C. Bioavailability and bioefficacy of
polyphenols in humans. I. Review of 97 bioavail
ability studies. Am J ClinNutr. 2005 Jan;81(1
Suppl):230S-42S.
Williamson G, Manach C. Bioavailability and bioeffi
cacy of polyphenols in humans. II. Review of 93
intervention studies. Am J ClinNutr. 2005 Jan;81(1
Suppl):243S-55S.
Spencer JP. Beyond antioxidants: the cellular and
molecular interactions of flavonoids and how these
underpin their actions on the brain. ProcNutr Soc.
2010 May;69(2):244-60.
Spencer JP. The impact of flavonoids on memory:
physiological and molecular considerations. Chem
Soc Rev. 2009 Apr;38(4):1152-61.
Spencer JP. The impact of fruit flavonoids on
memory and cognition. Br J Nutr. 2010 Oct; 104
Suppl 3:S40-7.
Fraga CG, Oteiza PI. Dietary flavonoids: Role of
(-)-epicatechin and related procyanidins in cell
signaling. Free RadicBiol Med. 2011 Aug 15;
51(4):813-23.
Hsieh HM, Wu WM, Hu ML. Soy isoflavones attenu
ate oxidative stress and improve parameters
related to aging and Alzheimer's disease in
C57BL/6J mice treated with D-galactose. Food
ChemToxicol. 2009 Mar;47(3):625-32.
Sarkaki A, Amani R, Badavi M, Moghaddam AZ,
Aligholi H, Safahani M, et al. Pre-treatment effect
of different doses of soy isoflavones on spatial
learning and memory in an ovariectomized animal
model of Alzheimer's disease. Pak J Biol Sci. 2008
Apr 15;11(8):1114-9.
Celec P, Ostatnikova D, Caganova M, Zuchova S,
Hodosy J, Putz Z, et al. Endocrine and cognitive
effects of short-time soybean consumption in
women. GynecolObstet Invest. 2005;59(2):62-6.
Celec P, Ostatnikova D, Hodosy J, Putz Z, Kudela M.
Increased one week soybean consumption affects
spatial abilities but not sex hormone status in men.
Int J Food SciNutr. 2007 Sep;58(6):424-8.

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

24.
25.
26.
27.
28.

29.

30.

31.

32.

33.

34.
35.

43

Ostatnikova D, Celec P, Hodosy J, Hampl R, Putz Z,
Kudela M. Short-term soybean intake and its effect
on steroid sex hormones and cognitive abilities.
FertilSteril. 2007 Dec;88(6):1632-6.
Fletcher RJ. Food sources of phyto-oestrogens and
their precursors in Europe. Br J Nutr. 2003 Jun;
89Suppl 1:S39-43.
Munro IC, Harwood M, Hlywka JJ, Stephen AM,
Doull J, Flamm WG, et al. Soy isoflavones: a safety
review. Nutr Rev. 2003 Jan;61(1):1-33.
Nielsen IL, Williamson G. Review of the factors
affecting bioavailability of soy isoflavones in
humans. Nutr Cancer. 2007;57(1):1-10.
Cederroth CR, Nef S. Soy, phytoestrogens and
metabolism: A review. Mol Cell Endocrinol. 2009
May 25;304(1-2):30-42.
Bastianetto S, Yao ZX, Papadopoulos V, Quirion R.
Neuroprotective effects of green and black teas
and their catechingallate esters against betaamyloid-induced toxicity. Eur J Neurosci. 2006
Jan;23(1):55-64.
Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh
MH, et al. The green tea polyphenol (-)-epigallocatechingallate attenuates beta-amyloid-induced
neurotoxicity in cultured hippocampal neurons. Life
Sci. 2001 Dec 21;70(5):603-14.
Levites Y, Amit T, Mandel S, Youdim MB. Neuropro
tection and neurorescue against Abeta toxicity and
PKC-dependent release of nonamyloidogenic
soluble precursor protein by green tea polyphenol
(-)-epigallocatechin-3-gallate. FASEB J. 2003 May;
17(8):952-4.
Kong AN, Yu R, Chen C, Mandlekar S, Primiano T.
Signal transduction events elicited by natural
products: role of MAPK and caspase pathways in
homeostatic response and induction of apoptosis.
Arch Pharm Res. 2000 Feb;23(1):1-16.
Koh SH, Kim SH, Kwon H, Park Y, Kim KS, Song
CW, et al. Epigallocatechingallate protects nerve
growth factor differentiated PC12 cells from
oxidative-radical-stress-induced apoptosis through
its effect on phosphoinositide 3-kinase/Akt and
glycogen synthase kinase-3. Brain Res Mol Brain
Res. 2003 Oct 21;118(1-2):72-81.
Xia Y, Ragan RE, Seah EE, Michaelis ML, Michaelis
EK. Developmental expression of N-methyl-Daspartate (NMDA)-induced neurotoxicity, NMDA
receptor function, and the NMDAR1 and gluta
mate- binding protein subunits in cerebellar
granule cells in primary cultures. Neurochem Res.
1995 May;20(5):617-29.
Owuor ED, Kong AN. Antioxidants and oxidants
regulated signal transduction pathways. Biochem
Pharmacol. 2002 Sep;64(5-6):765-70
Levites Y, Amit T, Youdim MB, Mandel S. Involve

VOL. 9 (2) APR - JUN 2014

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

ment of protein kinase C activation and cell
survival/ cell cycle genes in green tea polyphenol
(-)-epigallocatechin 3-gallate neuroprotective
action. J Biol Chem. 2002 Aug 23; 277(34):
30574-80.
Schroeter H, Spencer JP, Rice-Evans C, Williams
RJ. Flavonoids protect neurons from oxidized
low-density-lipoprotein-induced apoptosis involving
c-Jun N-terminal kinase (JNK), c-Jun and caspase3. Biochem J. 2001 Sep 15;358(Pt 3):547-57.
Satoh J, Kuroda Y. Beta-catenin expression in
human neural cell lines following exposure to
cytokines and growth factors. Neuropathology.
2000 Jun;20(2):113-23.
Wang CN, Chi CW, Lin YL, Chen CF, Shiao YJ. The
neuroprotective effects of phytoestrogens on
amyloid beta protein-induced toxicity are mediated
by abrogating the activation of caspase cascade in
rat cortical neurons. J Biol Chem. 2001 Feb 16;
276(7):5287-95.
Ma TC, Campana A, Lange PS, Lee HH, Banerjee
K, Bryson JB, et al. A large-scale chemical screen
for regulators of the arginase 1 promoter identifies
the soy isoflavonedaidzeinas a clinically approved
small molecule that can promote neuronal protec
tion or regeneration via a cAMP-independent
pathway. J Neurosci. 2010 Jan 13;30(2):739-48.
Hirohata M, Ono K, Takasaki J, Takahashi R, Ikeda
T, Morinaga A, et al. Anti-amyloidogenic effects of
soybean isoflavones in vitro: Fluorescence spec
troscopy demonstrating direct binding to Abeta
monomers, oligomers and fibrils. BiochimBiophys
Acta. 2012 Aug;1822(8):1316-24.
Radovic B, Mentrup B, Kohrle J. Genistein and
other soya isoflavones are potent ligands for
transthyretin in serum and cerebrospinal fluid. Br J
Nutr. 2006 Jun;95(6):1171-6.
Li X, Buxbaum JN. Transthyretin and the brain
re-visited: is neuronal synthesis of transthyretin
protective in Alzheimer's disease? MolNeurode
gener. 2011;6:79
Ma W, Yuan L, Yu H, Ding B, Xi Y, Feng J, et al.
Genistein as a neuroprotective antioxidant attenu
ates redox imbalance induced by beta-amyloid
peptides 25-35 in PC12 cells. Int J DevNeurosci.
2010 Jun;28(4):289-95
Valles SL, Borras C, Gambini J, Furriol J, Ortega A,
Sastre J, et al. Oestradiol or genistein rescues
neurons from amyloid beta-induced cell death by
inhibiting activation of p38. Aging Cell. 2008 Jan;
7(1):112-8.
Valles SL, Dolz-Gaiton P, Gambini J, Borras C, Lloret
A, Pallardo FV, et al. Estradiol or genistein prevent
Alzheimer's
disease-associated
inflammation
correlating with an increase PPAR gamma expres

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

46.

47.

48.

49.
50.

51.

52.

53.

54.
55.

56.

57.

58.

44

sion in cultured astrocytes. Brain Res. 2010 Feb 2;
1312:138-44.
Kuiper GG, Lemmen JG, Carlsson B, Corton JC,
Safe SH, van der Saag PT, et al. Interaction of
estrogenic chemicals and phytoestrogens with
estrogen receptor beta. Endocrinology. 1998 Oct;
139(10):4252-63.
Shughrue PJ, Lane MV, Merchenthaler I. Compara
tive distribution of estrogen receptor-alpha and
-beta mRNA in the rat central nervous system. J
Comp Neurol. 1997 Dec 1;388(4):507-25.
Gonzalez M, Cabrera-Socorro A, Perez-Garcia CG,
Fraser JD, Lopez FJ, Alonso R, et al. Distribution
patterns of estrogen receptor alpha and beta in the
human cortex and hippocampus during develop
ment and adulthood. J Comp Neurol. 2007 Aug
20;503(6):790-802.
Nussbaum RL, Ellis CE. Alzheimer's disease and
Parkinson's disease. N Engl J Med. 2003 Apr
3;348(14):1356-64.
Barberger-Gateau P, Raffaitin C, Letenneur L, Berr
C, Tzourio C, Dartigues JF, et al. Dietary patterns
and risk of dementia: the Three-City cohort study.
Neurology. 2007 Nov 13;69(20):1921-30.
Sofi F, Abbate R, Gensini GF, Casini A. Accruing
evidence on benefits of adherence to the Mediter
ranean diet on health: an updated systemic review
to meta-analysis. Am J ClinNitr. 2010 Nov:92(5)
Tangney CC, Kwasny MJ, Li H et al. Adherence to a
Mediterranean-type dietary pattern and cognitive
decline in a community population. Am J ClinNutr.
2011 Mar;93(3):601-7
Rendeiro C, Vauzour D, Rattray M, Waffo-Teguo P,
Merillon JM, Butler LT, et al. Dietary levels of pure
flavonoids improve spatial memory performance
and increase hippocampal brain-derived neuro
trophic factor. PLoS One. 2013;8(5):e63535.
Burke SN, Barnes CA. Neural plasticity in the
ageing brain. Nat Rev Neurosci. 2006 Jan;
7(1):30-40.
Chun OK, Chung SJ, Claycombe KJ, Song WO.
Serum C-reactive protein concentrations are
inversely associated with dietary flavonoid intake in
U.S. adults. J Nutr. 2008 Apr;138(4):753-60.
Ozawa M, Ninomiya T, Ohara T, Doi Y, Uchida K,
Shirota T, et al. Dietary patterns and risk of demen
tia in an elderly Japanese population: the Hisay
ama Study. Am J ClinNutr. 2013 May; 97(5):
1076-82.
Ho SC, Chan AS, Ho YP, So EK, Sham A, Zee B, et
al. Effects of soy isoflavone supplementation on
cognitive function in Chinese postmenopausal
women: a double-blind, randomized, controlled trial.
Menopause. 2007 May-Jun;14(3 Pt 1):489-99.
Duffy R, Wiseman H, File SE. Improved cognitive

VOL. 9 (2) APR - JUN 2014

59.

60.

function in postmenopausal women after 12 weeks
of consumption of a soya extract containing isofla
vones. Pharmacol BiochemBehav. 2003 Jun;
75(3):721-9.
Henderson VW, St John JA, Hodis HN, Kono N,
McCleary CA, Franke AA, et al. Long-term soy
isoflavone supplementation and cognition in
women: a randomized, controlled trial. Neurology.
2012 Jun 5;78(23):1841-8.
Casini ML, Marelli G, Papaleo E, Ferrari A,

61.

D'Ambrosio F, Unfer V. Psychological assessment of
the effects of treatment with phytoestrogens on
postmenopausal women: a randomized, doubleblind, crossover, placebo-controlled study. Fertil
Steril. 2006 Apr;85(4):972-8.
Kato-Kataoka A, Sakai M, Ebina R, Nonaka C,
Asano T, Miyamori T. Soybean-derived phosphati
dylserine improves memory function of the elderly
Japanese subjects with memory complaints. J
ClinBiochemNutr. 2010 Nov;47(3):246-55.

Conflict of Interest: Author declares no conflict of interest.
Funding Disclosure: Nil
Author’s Contribution:
Sara Habib: Study concept and design, data collection, data analysis, manuscript writing,
manuscript review
Asad Ali Khan Afridi: Data collection, data analysis, manuscript writing, manuscript review
Mohammad Wasay: Manuscript writing, manuscript review
Romaina Iqbal: Study concept and design, protocol writing, data collection, data analysis,
manuscript writing, manuscript review

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

45

VOL. 9 (2) APR - JUN 2014

